NCR Drug, Medical Device Makers Can Use Gensets Freely

Mumbai : Manufacturers of medical devices, medical equipment and medicines can use diesel generator sets to run their production facilities irrespective of the curbs imposed by pollution control agencies in the National Capital Region (NCR) from time to time.

The Central government’s Commission for Air Quality Management in National Capital Region & Adjoining Areas has added these categories, along with medical services, as activities that are exempted from such restrictions.

The commission, in a directive on December 13, said activities or services categorised as emergency will be permitted to use diesel generator sets as an exception in NCR whenever orders for a ban are issued.

The commission’s recent directive for shutting down industrial units that use diesel generator sets in NCR as a temporary measure to bring down pollution levels in Delhi and adjoining areas had threatened to disrupt production of syringes and needles at India’s largest syringe maker located in Faridabad near Delhi. Though a clarification had allowed production of syringes, the latest directive has cleared the uncertainty regarding such curbs in future, increasing the attractiveness of NCR and adjoining areas as a medical device manufacturing location. Uttar Pradesh government, for instance, has been trying to develop a medical device park in Greater Noida.

The other category of activities and services that are permitted to use diesel generator sets include metro rail services, including trains and stations, airports, inter-state bus terminals, sewerage treatment plants, water pumping stations, national security and defence related installations, projects of national importance, elevators and escalators and railway services. The commission has asked all enforcement agencies like state pollution control boards to comply with its new directive.

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad